Clinical trial · Observational
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
NCT03735511CI-TRIAL-00044829unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Carcinoma | Gastric Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 2015-2018
- description
- Overall Survival
Secondary outcomes (3)
- measure
- Objective Response Rate
- timeFrame
- 2015-2018
- description
- Objective Response Rate
- measure
- Disease Control Rate
- timeFrame
- 2015-2018
- description
- Disease Control Rate
- measure
- Progression-Free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma; 2. Patients received apatinib treatment at least once. Exclusion Criteria: 1\. No specific exclusion criteria in this real world study.
References
Publications (0)
Data not yet available
No reference posted for this study.